Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Democrats lean on drug pricing as ACA repeal looms

Democrats are showing little interest in cooperating with the Republicans who control Congress on legislation to dismantle the Obamacare health insurance law, but some are signaling a willingness to collaborate on action to curb rising drug prices.

Read More »

Sinovac Biotech CEO Reportedly Bribed Chinese FDA, Buyout Offers Could Be in Jeopardy

An article published on Seeking Alpha outlining a Chinese bribery verdict against SinoVac’s chief executive officer has sparked two U.S. law firms to announce an investigation concerning possible violations of federal securities laws by the Chinese company on behalf of shareholders.

Read More »

Alexion Reports Failed Soliris Trial

Grappling with allegations of improper sales practices, Alexion Pharmaceuticals has announced a failure of a Phase II/III trial for expanded use of Soliris.

Read More »

Battle for Actelion: Sanofi is Out, Johnson & Johnson is Back In

The end of 2016 appears to have at least one more unpredictable story – who is going to buy Swiss-based Actelion Pharmaceuticals?

Read More »

Massachusetts Biotech OvaScience Slashes 30% of Workforce; CEO and COO Resign

OvaScience, a fertility-focused bitotech, will undergo a corporate restructuring that is resulting in the termination of 30 percent of its workforce and causing the resignation of the company’s chief executive and chief operations officers.

Read More »

Sun Pharma to Acquire Novartis Cancer Product

India’s largest drugmaker, Sun Pharmaceutical Industries, is buying the skin cancer drug Odomzo from Switzerland-based Novartis for $175 million upfront.

Read More »

The 7 Worst Clinical Disasters of 2016

It’s expected that a large number of clinical trials will result in failure. 2016 saw numerous trial failures, but analysts at The Motley Fool selected seven failures that are expected to have a direct impact on the forward outlooks of the companies involved.

Read More »

Roche’s emicizumab hemophilia drug succeeds in trial

Roche Holding AG’s emicizumab drug for treating hemophilia A showed it worked in a phase III study, the Swiss drugmaker said.

Read More »

U.S. says 6.4 million signed up for Obamacare from Nov. 1-Dec. 19

Roughly 6.4 million consumers signed up for Obamacare insurance on from Nov. 1 to Dec. 19, 2016, indicating “clear demand for quality, affordable coverage,” the U.S. government said.

Read More »

Investors see Biogen CEO choice as friendly to potential takeover

The surprise selection of Michel Vounatsos to run Biogen Inc. signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.

Read More »

GSW Releases 2017 Pharma, Health and Wellness Trends Forecast

Full-service healthcare communications agency GSW released its annual trends reports series, identifying emerging trends to help marketing professionals and their brand managers understand how consumer expectations are changing.

Read More »

Inovio Zika vaccine evokes robust response in early human study

Inovio Pharmaceuticals Inc. said its experimental Zika vaccine induced robust immune responses in an early-stage study in human volunteers who have not been infected with the virus.

Read More »

Colombia cuts price of Novartis cancer drug by 44 percent

Colombia’s government has lowered the price of Novartis cancer drug imatinib by nearly half in a bid to cut healthcare costs after failed price negotiations with the Swiss company.

Read More »

Merrimack ends breast cancer drug study

Merrimack Pharmaceuticals will stop a study for advanced breast cancer after an analysis suggested its drug would unlikely show superiority over chemo.

Read More »

Ophthotech Clinical Disaster Spurs Layoffs

Ophthotech is cutting up to 135 jobs following the failure of its two Phase III clinical trials combining the company’s Fovista and Genentech’s Lucentis to treat wet AMD.

Read More »

Merus Forges $200+ Million Research Pact With Incyte

Incyte Corporation and Merus NV announced they have signed a global, strategic collaboration deal. The two companies will identify, discover and develop bispecific antibodies for immuno-oncology purposes.

Read More »

Sumitomo Dainippon to acquire Tolero Pharmaceuticals

Sumitomo Dainippon Pharma Co. Ltd. is plunking down up to $780 million to acquire Utah-based Tolero Pharmaceuticals and its oncology therapies.

Read More »

Ono warns on profit after government halves price of cancer drug Opdivo

Ono Pharmaceutical Co. cut its annual profit outlook by a quarter, hit by the Japanese government’s decision to halve the price of cancer drug Opdivo that it co-developed with Bristol Myers Squibb Co.

Read More »

FDA extends review for Roche MS drug Ocrevus

Swiss drugmaker Roche said the U.S. Food and Drug Administration (FDA) has extended until March 28, 2017, the date for reviewing its application for multiple sclerosis drug Ocrevus.

Read More »

Allergan to buy Acelity’s tissue unit LifeCell

Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom